Delivery Order SPE2DR25D2006-SPE2DR26F56LC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens, with a ceiling value of $1,259.18. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The order is set for ultimate completion by November 21, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a Delivery Order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Actemra ActPen 162 mg/0.9 ml auto-injectors with a ceiling value of $8,352.14. This is a firm fixed-price order with an ultimate completion date of December 1, 2025, and represents a non-competitive set-aside delivery against AmerisourceBergen's existing indefinite delivery contract (IDC) vehicle. The place of performance is AmerisourceBergen's corporate office location in...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Actemra ActPen 162 mg/0.9 ml auto-injector pens with a ceiling value of $18,556.74. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 12, 2025, to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens, with a ceiling value of $1,205.54 and a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of November 4, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order...
- The Defense Logistics Agency awarded a $2,287.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector units. The contract, which carries an ultimate completion date of October 17, 2025, represents a non-set-aside competitive award with performance to be executed at the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,287.88 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order does not utilize a set-aside designation. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors with a ceiling value of $4,575.76. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The award is issued from the company's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 5, 2025. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,906.05 on September 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DR25D2006Indefinite Delivery Contract
- SPE2DR25D2006-SPE2DR26F56LCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens with a ceiling value of $1,205.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitive award, with an ultimate completion date of December 4, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal healthcare systems. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime contract vehicle designated SPE2DX and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Actemra (tocilizumab), a biologic immunosuppressant, represents one of the specialized medications within the company's extensive portfolio of brand-name and generic drugs, vaccines, and medical commodities delivered to the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 12/2/25 |